27271087|t|Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6- week, placebo-controlled study
27271087|a|Asenapine is a second generation anti-psychotic approved in the USA in 2009 for the treatment of schizophrenia, but its efficacy has not been proven in Asian patients. The objectives of this study are to evaluate the efficacy and tolerability of asenapine in Asian patients experiencing an acute exacerbation of schizophrenia. In this prospective, double-blind study, patients in Japan, Korea, and Taiwan were randomized (1:1:1) to asenapine 5 mg twice daily (bid), 10 mg bid or placebo for 6 weeks after a 3- to 7- day washout / screening period. The primary endpoint was the mean change in the positive and negative syndrome scale (PANSS) total score from baseline to day 42/ treatment end. Of the 532 participants randomized, 530 received treatment. The primary endpoint was significantly greater with asenapine 5 and 10 mg bid than with placebo (-12.24 and -14.17 vs. -0.95; p < 0.0001). The results of secondary endpoints including PANSS negative subscale scores and PANSS responders at the end of treatment supported the results of the primary endpoint. There were no significant differences in the incidence of treatment -emergent adverse events reported with asenapine 5 and 10 mg bid and placebo (84.6, 80.7, and 81.6 %). There was a mean (± standard deviation) change in weight of -1.76 ± 2.45 kg for placebo, +0.42 ± 2.65 kg for asenapine 5 mg bid, and +0.81 ± 2.89 kg for asenapine 10 mg bid group. Asenapine was effective and generally well tolerated when used for the treatment of acute exacerbations of schizophrenia in Asian patients.
27271087	23	32	asenapine	T103	UMLS:C2000088
27271087	36	41	Asian	T098	UMLS:C0078988
27271087	81	94	schizophrenia	T038	UMLS:C0036341
27271087	98	109	multicentre	T062	UMLS:C0206012
27271087	111	121	randomized	T062	UMLS:C0206034
27271087	123	135	double-blind	T062	UMLS:C0013072
27271087	171	180	Asenapine	T103	UMLS:C2000088
27271087	204	218	anti-psychotic	T103	UMLS:C0040615
27271087	235	238	USA	T082	UMLS:C0041703
27271087	255	264	treatment	T058	UMLS:C0087111
27271087	268	281	schizophrenia	T038	UMLS:C0036341
27271087	323	328	Asian	T098	UMLS:C0078988
27271087	343	353	objectives	T170	UMLS:C0018017
27271087	362	367	study	T062	UMLS:C2603343
27271087	417	426	asenapine	T103	UMLS:C2000088
27271087	430	435	Asian	T098	UMLS:C0078988
27271087	483	496	schizophrenia	T038	UMLS:C0036341
27271087	519	537	double-blind study	T062	UMLS:C0013072
27271087	551	556	Japan	T082	UMLS:C0022341
27271087	558	563	Korea	T082	UMLS:C0022771
27271087	569	575	Taiwan	T082	UMLS:C0039260
27271087	581	591	randomized	T062	UMLS:C0034656
27271087	603	612	asenapine	T103	UMLS:C2000088
27271087	650	657	placebo	T062	UMLS:C1706408
27271087	723	739	primary endpoint	T103	UMLS:C2986535
27271087	767	803	positive and negative syndrome scale	T170	UMLS:C0451383
27271087	805	810	PANSS	T170	UMLS:C0451383
27271087	849	858	treatment	T058	UMLS:C0087111
27271087	875	887	participants	T098	UMLS:C0679646
27271087	888	898	randomized	T062	UMLS:C0034656
27271087	913	922	treatment	T058	UMLS:C0087111
27271087	928	944	primary endpoint	T103	UMLS:C2986535
27271087	976	985	asenapine	T103	UMLS:C2000088
27271087	1012	1019	placebo	T062	UMLS:C1706408
27271087	1108	1113	PANSS	T170	UMLS:C0451383
27271087	1143	1148	PANSS	T170	UMLS:C0451383
27271087	1174	1183	treatment	T058	UMLS:C0087111
27271087	1213	1229	primary endpoint	T103	UMLS:C2986535
27271087	1289	1298	treatment	T058	UMLS:C0087111
27271087	1309	1323	adverse events	T038	UMLS:C0877248
27271087	1338	1347	asenapine	T103	UMLS:C2000088
27271087	1368	1375	placebo	T062	UMLS:C1706408
27271087	1482	1489	placebo	T062	UMLS:C1706408
27271087	1511	1520	asenapine	T103	UMLS:C2000088
27271087	1555	1564	asenapine	T103	UMLS:C2000088
27271087	1582	1591	Asenapine	T103	UMLS:C2000088
27271087	1653	1662	treatment	T058	UMLS:C0087111
27271087	1689	1702	schizophrenia	T038	UMLS:C0036341
27271087	1706	1711	Asian	T098	UMLS:C0078988